Carl G, Reitz D, Schonecker S, Pazos M, Freislederer P, Reiner M
Technol Cancer Res Treat. 2018; 17:1533033818806002.
PMID: 30453842
PMC: 6243634.
DOI: 10.1177/1533033818806002.
Gawish A, Chughtai A, Eble M
Strahlenther Onkol. 2018; 195(5):383-392.
PMID: 30334066
DOI: 10.1007/s00066-018-1381-4.
Franzone P, Fiorentino A, Barra S, Cante D, Masini L, Cazzulo E
Radiol Med. 2016; 121(12):958-965.
PMID: 27601141
DOI: 10.1007/s11547-016-0674-x.
Cacicedo J, Dal Pra A, Alongi F, Navarro A
Eur J Clin Nutr. 2015; 69(7):757-60.
PMID: 25920425
DOI: 10.1038/ejcn.2015.65.
Bertolaccini L, Terzi A, Ricchetti F, Alongi F
Ann Transl Med. 2015; 3(2):25.
PMID: 25738145
PMC: 4322166.
DOI: 10.3978/j.issn.2305-5839.2015.01.06.
Initial experience of hypofractionated radiation retreatment with true beam and flattening filter free beam in selected case reports of recurrent nasopharyngeal carcinoma.
Alongi F, Clerici E, Pentimalli S, Mancosu P, Scorsetti M
Rep Pract Oncol Radiother. 2014; 17(5):262-8.
PMID: 24669306
PMC: 3885887.
DOI: 10.1016/j.rpor.2012.07.012.
The PROCAINA (PROstate CAncer INdication Attitudes) Project (Part I): a survey among Italian radiation oncologists on postoperative radiotherapy in prostate cancer.
Alongi F, De Bari B, Franco P, Ciammella P, Chekrine T, Livi L
Radiol Med. 2013; 118(4):660-78.
PMID: 23358818
DOI: 10.1007/s11547-012-0913-8.
Moderate hypofractionation and simultaneous integrated boost with volumetric modulated arc therapy (RapidArc) for prostate cancer. Report of feasibility and acute toxicity.
Alongi F, Fogliata A, Navarria P, Tozzi A, Mancosu P, Lobefalo F
Strahlenther Onkol. 2012; 188(11):990-6.
PMID: 23053143
DOI: 10.1007/s00066-012-0171-7.
Short-term outcomes of CyberKnife therapy for advanced high-risk tumors: A report of 160 cases.
Wang Y, Wang Y, Jiang P, Ma J, Qu Z, Wang X
Exp Ther Med. 2012; 3(4):725-727.
PMID: 22969959
PMC: 3438800.
DOI: 10.3892/etm.2012.451.